Pharmacist anti-MRSA time-outs cut use mainly in emergency departments

This interrupted time-series shows a pharmacist-led 72-hour anti-MRSA reassessment reduces vancomycin days of therapy and therapeutic drug monitoring burden in high-acceptance areas, offering a resource-conscious targeting strategy for stewardship programs.

vancomycinteicoplaninlinezoliddaptomycinanti-MRSA agentsantimicrobial stewardshipantibiotic time-outtherapeutic drug monitoringinterrupted time-seriesMRSApharmacist-led intervention Pharmacokinetics / TDM

Background Information

Targeted pharmacist-led interventions reduce intensive care antibiotic use.

Targeted antimicrobial stewardship can optimize antibiotic use and resource allocation, especially in resource-limited settings. Antibiotic days of therapy decreased significantly in emergency medicine and critical care, with high acceptance rates; therapeutic drug monitoring tests also decreased. Pharmacist-led interventions are effective in specific departments, emphasizing the importance of strategic targeting for optimal outcomes without impacting stay duration or mortality. Focused antimicrobial time-outs effectively reduce unnecessary antibiotic use in key hospital areas.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Yamamoto R, Tagashira Y, An DD, Enatsu Y, Satake M, Aiso Y, Gu Y

Citation: Yamamoto R, Tagashira Y, An DD, et al. Where antibiotic time-outs work: department- and ward-stratified effects of a pharmacist-led anti-MRSA time-out. Antimicrobial stewardship & healthcare epidemiology : ASHE. 2026;6(1):e208. doi:10.1017/ash.2026.10778

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →